REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I see this at 150p within the next 12 months
The industry is massive and hungry for smaller and more complicated chips tom power the next generation of AI enabled and IOT products like smartphones satellites radar smart rings electric scooters EV's etc
The NHS spend close to £100 million a year on PDE 5 inhibitors
A 20% market share of that is £20 million a year
Add the fact that 20% of ED sufferers are on medications that contra indicate with PDE 5 Inhibitors and that is millions of pounds more sales
Last year sales were £3 million from scratch.
Trinity Delta are forecasting global peak sales of nearly £500 million
That is 166 times more and the share price will be way ahead of that
Ignore the recent "innocent bystanders" offering advice that is always with a negative tone.
This will multi bag
Our valuation of 121p per share, suggests that the Eroxon opportunity is not reflected in the current share price. Our model includes peak US sales of $350m with partner Haleon and $100-130m in each of Europe and in Other Regions.
So they are up to half a billion dollars peak sales.I think it will easily be double that which would correlate with a 20% market share and the fact that 20% of men are contra indicated to Viagra and Cialis